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Suppression of T Cell Activation and Collagen
Accumulation by an Anti-IFNAR1 mAb, Anifrolumab,
in Adult Patients with Systemic Sclerosis
Xiang Guo1, Brandon W. Higgs1, Anne C Bay-Jensen2, Morten A. Karsdal2, Yihong Yao1, Lorin K. Roskos1 and
Wendy I. White1
Type I IFNs are implicated in the pathophysiology of systemic sclerosis (SSc). Recently, a Phase I open-label trial
was conducted with an anti-IFNAR1 receptor antibody (anifrolumab) in adult SSc patients. In this study, we aim to
assess the downstream effects of anifrolumab and elucidate the role of type I IFN in SSc. Serum proteins and
extracellular matrix (ECM) markers were measured in relation to IFN pathway activation status and SSc disease
activity. Our results demonstrated a robust overexpression of multiple serum proteins in SSc patients,
particularly those with an elevated baseline type I IFN gene signature. Anifrolumab administration was associated
with signiﬁcant downregulation of T cell–associated proteins and upregulation of type III collagen degradation
marker. Whole-blood and skin microarray results also indicated the inhibition of T cell receptor and ECM–related
transcripts by anifrolumab. In summary, our study demonstrates suppressive effects of anifrolumab on T cell
activation and collagen accumulation through which tissue ﬁbrosis may be reduced in SSc patients. The
relationship between these peripheral markers and the clinical response to anifrolumab may be examined in
larger double-blind, placebo-controlled trials.
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INTRODUCTION
Systemic sclerosis (SSc) is a rare, multisystem autoimmune
disease of unknown etiology, characterized by vascular
alterations, immunological disturbances, and ﬁbrosis of the
skin and internal organs. T cell and macrophage inﬁltration
has been demonstrated in skin biopsies of SSc patients
preceding ﬁbrosis (Prescott et al., 1992). Endothelial cell
activation and adhesion molecule overexpression are also
evident in SSc, leading to the migration of immune cells into
the extravascular tissue (Sato, 1999). T cell–derived cytokines
are important factors that drive the production of extracellular
matrix (ECM) components by ﬁbroblasts resulting in excessive
ﬁbrosis in SSc patients (O'Reilly et al., 2012). The interaction
between T cells and ﬁbroblasts through CD40LG-CD40
signaling is critical for ﬁbroblast activation and proliferation
(Yellin et al., 1995; Kawai et al., 2008), which also has a
synergistic effect on the proﬁbrotic action of T cell–derived
cytokines (Atamas et al., 2002). An open-label trial has
demonstrated the association between type III collagen
reduction and skin softening observed in several patients on
T cell–directed therapy (Frances et al., 1988).
IFNs are key cytokines involved in innate and adaptive
immunity. The dysregulation of type I IFN signaling in SSc has
been demonstrated by genetic linkage, as well as molecular
and cellular data (Coelho et al., 2008; Eloranta et al., 2010;
Carmona et al., 2013; Liu et al., 2013). Increased levels of
IFN–inducible transcripts and chemokines have been asso-
ciated with the more severe form of the disease (Eloranta
et al., 2010; Higgs et al., 2011). IFN therapy has also been
implicated in the development of SSc (Solans et al., 2004).
However, the mechanisms by which the dysregulated IFN
signaling contributes to SSc pathogenesis and severity remain
unknown.
Anifrolumab (previously known as MEDI-546) is an
investigational human IgG1κ mAb directed against subunit
1 of the type I IFN receptor. Recently, a Phase I open-label
clinical trial was completed in 34 adult SSc patients who
received single (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0mg kg− 1) or
four weekly intravenous doses (0.3, 1.0, or 5.0 mg kg− 1 per
week) of anifrolumab (Study MI-CP180). The safety and
tolerability proﬁle observed in this study supports further
clinical development of anifrolumab (Goldberg et al., 2014).
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Neutralization of a type I IFN gene signature by anifrolumab
has also been demonstrated in both blood and skin biopsies
(Goldberg et al., 2014). Our current study aims to assess
downstream effects of anifrolumab and identify potential
biomarkers for anti-IFN therapy in SSc patients.
Serum samples were procured from the SSc trial of
anifrolumab, along with another Phase I SSc trial (Study MI-
CP200) for an anti-CD19 antibody (MEDI-551) to help
establish speciﬁcity of IFN involvement. The effects of
anifrolumab on SSc–associated proteins were determined
relative to IFN gene signature neutralization. ECM turnover
markers were evaluated pre- and post administration to assess
the potential effects of anifrolumab on ﬁbrosis. Finally,
differentially expressed transcripts were identiﬁed, as were
upstream regulators and enriched pathways in whole-blood
and skin biopsies after anifrolumab administration.
RESULTS
Dysregulated serum proteins and association with clinical
assessments in SSc patients
Serum samples were procured from SSc patients enrolled in
two Phase I trials for anifrolumab and MEDI-551, respectively.
The mean modiﬁed Rodnan skin score (mRSS) and the Health
Assessment Questionnaire-Disability Index (HAQ-DI) were
similar for patients receiving placebo, MEDI-551, or anifro-
lumab (P40.05). Most participants were female, white, and
had diffuse cutaneous SSc and Raynaud’s phenomenon.
Positive anti-nuclear, anti-cardiolipin, and anti-SCL-70 anti-
bodies were found in similar percentages of patients among
three treatment groups (P40.05). There was no signiﬁcant
difference in the percentage of subjects receiving stable doses
of antineoplastic and immunomodulation agents (azathiopr-
ine, methotrexate, or mycophenolate), systemic steroid
(prednisone, methylprednisolone, or hydrocortisone), or
anti-malarials for placebo, MEDI-551, and anifrolumab
treatment groups (P40.05) (Table 1).
We measured 93 proteins in serum samples at baseline
from 26 SSc patients enrolled in anifrolumab trial, 21 SSc
patients enrolled in MEDI-551 trial, and 30 healthy controls
(HCs) recruited separately. Among 47 SSc patients, 31 had an
elevated IFN gene signature (IFN-hi) and 15 did not (IFN-lo),
whereas one patient had gene expression data missing. IFN-hi
patients showed signiﬁcantly higher mRSS and HAQ-DI
compared with IFN-lo patients (Po0.01), suggesting an
association between IFN activity and SSc disease activity.
There was no signiﬁcant difference in age, gender, and race
among HCs, IFN-lo, and IFN-hi SSc patients (P40.05).
Of the 93 measured proteins, 25 showed serum levels
below the lowest limit of quantitation in 470% of all
samples. No signiﬁcant difference was found for the distribu-
tions of these negative proteins among HCs, IFN-lo, and IFN-
hi SSc patients; hence, they were excluded from downstream
analysis. Principal component analysis of the 68 remaining
proteins demonstrated distinct proteomic features among
HCs, IFN-lo, and IFN-hi SSc patients (Supplementary Figure
S1 online). Comparison of HCs and all SSc patients identiﬁed
37 proteins with signiﬁcantly higher concentrations in SSc
patients (Benjamin–Hochberg (BH) Po0.05). Then, analysis
of variance analysis followed by pairwise comparison
demonstrated higher serum levels of 38 proteins in IFN-hi
compared with IFN-lo patients or HCs (BH Po0.05). In total,
41 unique proteins were shown to be upregulated in IFN-hi
and/or all SSc patients, among whom 25 are inducible
by IFN (Rusinova et al., 2013). Interestingly, 12 proteins
had signiﬁcantly higher concentrations in IFN-hi but not
IFN-lo patients compared with HCs, suggesting a unique
proteomic feature of IFN-hi SSc patients (Supplementary
Table S1 online).
We then assessed association of the 41 dysregulated
proteins with mRSS, HAQ-DI, percent of predicted diffusing
capacity for carbon monoxide (DLcoP), percent of predicted
forced vital capacity, and three patient reported outcomes
included in the European Disease Activity Index (Δ-skin,
Δ-vascular, Δ-heart/lung) (Valentini et al., 2001) in SSc
patients by Spearman’s correlation analysis. Although
peroxiredoxin-4 showed signiﬁcant correlation with mRSS,
CCL11 may be associated with lung disease evidenced by its
negative correlation with DLcoP (BH Po0.05). In addition,
ﬁve proteins (TIMP1, SPP1, IL-2RA, TNFR2, and CCL21)
demonstrated signiﬁcant correlation with HAQ-DI, and
IL-13 was related to Δ-vascular (BH Po0.05) (Table 2).
We also evaluated the difference of serum protein levels
in the presence of anti-nuclear antibody, anti-Scl70 antibody,
or four European Disease Activity Index components (scler-
edema, digital necrosis, arthritis, hypocomplementaemia),
respectively (Valentini et al., 2001). The only association that
was uncovered was that MCP1 had signiﬁcantly higher serum
level in the 4 SSc patients with digital necrosis compared
with the 43 patients without (fold change (FC)= 1.69, BH
P= 0.003).
Effects of anifrolumab on serum proteins levels of SSc patients
Effects of placebo, MEDI-551, and anifrolumab on the 41 SSc-
related proteins were assessed by paired-comparison of pre-
and post treatment serum samples from patients enrolled in
MI-CP200 and MI-CP180 trials. Anifrolumab administration
was associated with decreased serum levels of four IFN
inducible proteins including B2M, CCL13, CXCL10, and
VCAM1, along with CD40LG, IL-2RA, and Ferritin (BH
Po0.05) (Supplementary Table S2 online and Figures 1a and
b). In contrast, MEDI-551 was associated with increased BAFF
(B cell-activating factor of the TNF family) level (BH Po0.05)
(Figure 1c), whereas no signiﬁcant change was observed on
other serum proteins. No consistent trend was seen in the
placebo group for any serum protein. The lack of a sufﬁciently
sized longitudinal placebo control group and mixing of data
from two independent trials prevented a direct comparison of
change in anifrolumab-treated patients with placebo- or
MEDI-551-treated patients. Although no clear trend could be
seen between dosing levels and the effect of anifrolumab on
serum proteins because of the small sample size for each
dosing regimen, Spearman’s analysis indicated signiﬁcant
correlation between IFN gene signature suppression and
downregulation of CXCL10 and CD40LG (Figures 1d and e),
suggesting an association between IFN blockade and CXCL10/
CD40LG downregulation after anifrolumab administration.
X Guo et al.
Effects of Type I IFN Blockade in SSc
www.jidonline.org 2403
ECM turnover markers in SSc patients
Serological markers of ECM remodeling hold great potential
as noninvasive markers for connective tissue diseases. In this
study, we evaluated a set of protein ﬁngerprint markers for
ECM turnover (Karsdal et al., 2013), along with two traditional
collagen synthesis markers (amino-terminal propeptide of
type I procollagen and amino-terminal propeptide of type III
procollagen (PIIINP)) in SSc patients. Comparison of 30 HCs
with 53 to 59 SSc patients at baseline demonstrated
signiﬁcantly higher serum levels of nine markers in SSc
subjects, including formation/degradation markers of type II,
III, IV, V, VI collagens, and matrix metalloproteinase (MMP)–
degraded biglycan. ECM accumulation is governed by the
dynamic balance of formation and degradation process of
each ECM component, and thus we calculated the ratio of
formation and degradation markers for bone and type III/ IV
collagens. Both PIIINP/C3M and PRO-C3/C3M ratios were
signiﬁcantly higher in SSc patients compared with HCs,
suggesting an excess accumulation of type III collagen in SSc
patients. In addition, the ratio of bone resorption marker
CTX-I and bone formation marker osteocalcin N-MID was
signiﬁcantly higher in SSc patients, suggesting bone loss in
these patients (Table 3).
As described in the previous section, we assessed associa-
tion of the 13 dysregulated ECM turnover markers with
various clinical and laboratory variables, including mRSS,
HAQ-DI, DLcoP, predicted forced vital capacity, Δ-skin,
Δ-vascular, Δ-heart/lung, presence of scleredema, digital
necrosis, arthritis, hypocomplementemia, anti-nuclear anti-
body, or anti-Scl70 antibody in SSc subjects. Signiﬁcant
correlation was found between HAQ-DI and type III collagen
synthesis markers. The turnover ratios of type III collagen
and bone also showed trends of correlation with HAQ-DI
(Table 3).
The PIIINP/C3M ratio was signiﬁcantly decreased after
treatment of anifrolumab but not MEDI-551 or placebo
(Figure 2a). The same was true for the PRO-C3/C3M ratio.
Table 1. Clinical and demographic features of systemic sclerosis patients
Category Feature Placebo (n=4) MEDI-551 (n= 24) Anifrolumab (n= 34)
Demographics Age (years) (mean± SD) 42.3±14.4 48.1± 8.9 47.4±12
Female (%) 50 70.8 79.4
White (%) 100 83.3 73.5
Clinical features Diffuse cutaneous systemic SSc (%) 75 87.5 94.1
Raynaud’s (%) 100 100 97.1
mRSS (mean± SD) 22.8± 7.5 23.0± 8.7 23.3±8.6
HAQ-DI (mean± SD) 1.44±0.92 1.04±0.83 1.23±0.7
Positive anti-nuclear antibody (%) 50 79.2 70.6
Positive anti-cardiolipin antibody (%) 0 3.6 5.9
Positive anti-Scl-70 antibody (%) 75 37.5 32.4
Concomitant medications Antineoplastic and immunomodulating agents (%) 50 37.5 35.3
Corticosteroids for systemic use (%) 0 20.8 35.3
Anti-malarials (%) 0 0 8.8
Abbreviations: HAQ-DI, Health Assessment Questionnaire-Disability Index; mRSS, modiﬁed Rodnan skin score; SSc, systemic sclerosis.
No signiﬁcant difference in age, gender, race, clinical features, and concomitant medication proﬁles among SSc patients who received placebo, MEDI-551,
and anifrolumab. respectively (P40.05).
Table 2. Correlation of serum protein levels with
disease severity and IFN activity
mRSS HAQ-DI DLcoP Δ-Vascular IFN score
PRDX4 0.43** 0.32* − 0.01 −0.03 0.49**
IL-2RA 0.35* 0.39** − 0.1 −0.18 0.24
TIMP1 0.29* 0.51** − 0.18 −0.06 0.39**
SPP1 (OPN) 0.26* 0.43** − 0.03 0.08 0.45**
CCL21 (6Ckine) 0.31* 0.38** − 0.18 0.04 0.21
TNFRSF1B (TNFR2) 0.13 0.39** 0.03 −0.11 0.26*
CCL11 (Eotaxin-1) 0.04 − 0.06 − 0.46** −0.24 − 0.09
IL-13 0.06 − 0.03 0.16 0.47** − 0.08
IFN score 0.22 0.35* − 0.02 0.14 —
Abbreviations: DLcoP, diffusing capacity for carbon monoxide; HAQ-DI,
Health Assessment Questionnaire-Disability Index; mRSS, modiﬁed
Rodnan skin score.
Spearman’s correlation coefﬁcients were used to assess association
between serum protein levels and mRSS, HAQ-DI, percent of predicted
DLcoP, patient reported worsening of vascular system as compared with
the previous month (Δ-vascular), along with whole-blood type I IFN gene
signature score. Bold: IFN-inducible protein. **BH Po0.05; *Unadjusted
Po0.05.
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Separate analysis of three type III collagen markers indicated
that anifrolumab was associated with increased C3M level
(Figure 2b), whereas no change was observed for two
formation markers, suggesting accelerated collagen degrada-
tion after anifrolumab treatment.
Regulation of peripheral and skin transcripts by anifrolumab
Using whole-blood microarray data, we identiﬁed 290
downregulated probe sets and 26 upregulated probe sets at
day 56 after anifrolumab administration in comparison with
predose transcript levels (false discovery rate o0.01, |FC|
41.5). Ingenuity pathway analysis identiﬁed the canonical
pathway—activation of IRF by cytosolic pattern recognition
receptors—as the most enriched pathway in anifrolumab-
regulated transcripts (BH P= 0.006). IFN signaling was the
second most enriched pathway among these transcripts (BH
P=0.01). Causal analysis applications within ingenuity path-
way analysis aim to identify upstream transcriptional regula-
tors that can explain the observed gene expression changes
(Kramer et al., 2014). Not surprisingly, multiple IFN sub-
types were shown to be inhibited by anifrolumab. More
interestingly, CD40LG was predicted to be suppressed by
anifrolumab, consistent with the serum proteomics results. T
cell receptor was also one of the upstream regulators
responsible for the observed down/upregulation of target
transcripts by anifrolumab (Supplementary Table S3 online).
Skin biopsies were collected at predose and day 28 only for
10 SSc subjects who received multiple doses of anifrolumab.
Using the same criteria as in whole-blood gene expression
analysis, anifrolumab affected the expression of many more
genes in the skin with 4,830 downregulated probe sets
and 274 upregulated probe sets (false discovery rate o0.01,
|FC|41.5). We selected 526 probe sets with more than 2-fold
suppression (Supplementary Table S4 online) for Gene Onto-
logy enrichment analysis (Maere et al., 2005). The results
demonstrated that epidermis development, cell adhesion, and
ECM organization were among the most enriched biological
processes in anifrolumab-suppressed skin transcripts (Supple-
mentary Figure S2 online). Interestingly, we observed signiﬁ-
cant decrease in transforming growth factor-β receptor 1
(TGF-βR1), TGF-βR2, and TGF-βR3 transcripts after adminis-
tration. Mediators of latent TGF-β activation—thrombo-
spondin and integrin—also showed reduced expression,
suggesting the suppression of TGF-β signaling by anifrolumab.
Multiple anifrolumab-suppressed transcripts are indeed TGF-
β-regulated genes, such as collagens α1 (I) and α1 (III),
ﬁbronectin, connective tissue growth factor, and cartilage
oligomeric matrix protein (Sargent et al., 2010). Ingenuity
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Figure 1. Effects of anifrolumab and MEDI-551 on serum protein markers. (a and b) Soluble CXCL10 and CD40LG levels were signiﬁcantly suppressed by
anifrolumab in systemic sclerosis (SSc) patients enrolled in the MI-CP180 study but not by placebo or MEDI-551 administration in SSc patients enrolled in the MI-
CP200 study. (c) In contrast, the serum BAFF level was signiﬁcantly increased after MEDI-551 but not placebo or anifrolumab administration. (d and e) The
reduction in CXCL10 and CD40LG level was signiﬁcantly correlated with whole-blood IFN gene signature neutralization in 23 SSc patients who received single
(0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg kg−1) or four weekly intravenous doses (0.3, 1.0, or 5.0 mg kg−1 per week) of anifrolumab. *BH Po0.05, ** BH Po0.01, and
*** BH Po0.001.
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upstream regulator analysis also suggested the suppression
of TGF-β1 by anifrolumab, with the lowest overlap P-value
of 3.05E−18 and activation z-score of − 4.36. Furthermore,
anifrolumab signiﬁcantly suppressed the expression of
TIMP1, TIMP2, and TIMP3 transcripts, which may be res-
ponsible for the accelerated degradation of type III collagen
described earlier through the activation of matrix metallo-
proteinases. The suppression of TGF-β-regulated transcripts
and TIMPs showed concordant pattern with type I IFN-
inducible transcripts, suggesting an association between IFN
blockade and inhibition of TGF-β signaling after anifrolumab
administration (Figure 3).
DISCUSSION
Our study of the serologic proteome in SSc subjects suggests a
distinct proteome proﬁle of IFN-hi SSc subjects compared
with IFN-lo SSc patients and HCs (Supplementary Figure S1
online). Overexpressed proteins in SSc subjects are involved
in various biological processes, including regulation of T cell
proliferation, activation, and movement. The soluble forms of
IL-2RA and CD40LG are predominantly released by proteo-
lytic cleavage from the activated CD4+ T cell surface.
CXCL10 and CXCL11 are CXCR3 receptor ligands that recruit
activated CD4+ and CD8+ T cells to sites of inﬂammation. In
agreement with our results, elevated levels of these proteins
have been reported previously in SSc subjects, which
correlate with different disease measures (Degiannis et al.,
1990; Steen et al., 1996; Komura et al., 2004; Antonelli et al.,
2008; Liu et al., 2013). Immunomodulatory functions of type I
IFN include the control of T helper type 1/T helper type 2
function and the regulation of CD8+ cytotoxic T cell activity
and memory. Our results demonstrated that anifrolumab
administration was associated with peripheral levels of
T cell–associated proteins and transcripts regulated by T cell
receptor in adult SSc patients, which suggest a suppressive
effect of IFN neutralization on T cell activation and/or
proliferation in SSc patients.
The hallmark of SSc is excessive ECM deposition in the
skin, lung, and other internal organs. During the pathological
remodeling of ECM, the tissue- and pathology-speciﬁc turn-
over products are released into circulation. Serological
markers of collagen synthesis have long been used to assess
ﬁbrosis progression in SSc (Hummers, 2010). Increased level
of PIIINP was an unfavorable predictor of survival in SSc
(Nagy and Czirjak, 2005), and a decrease in PIIINP levels
has been reported after the use of immunosuppressant
(Heickendorff et al., 1995) or anti-tumor necrosis factor-α
body (Denton et al., 2009). ECM accumulation depends on
the dynamic balance of synthesis and degradation of each
ECM component. Our study indicates increased level of
several MMP–degraded neoepitope markers for collagen and
biglycan in SSc subjects (Table 3). The ratio of type III
Table 3. Serum markers for the extracellular matrix turnover
Assay name Target Reference Mean FC (SSc/HC) ρ (HAQ-DI)
PINP N-terminal propeptide of type I collagen Veidal et al., 2010 1.19 —
C1M MMP-2/9/13–degraded type I collagen Leeming et al., 2011 1.29 —
CTX-I Cathepsin K–degraded type I collagen Rosenquist et al., 1998 2.59**** 0.26*
C2M MMP–degraded type II collagen Bay-Jensen et al., 2011 1.58**** 0.11
PIIINP N-terminal propeptide of type III collagen Trocme et al., 2006 1.74**** 0.42**
PRO-C3 N-protease-mediated cleavage of PIIINP Nielsen et al., 2013 1.51*** 0.33**
C3M MMP-9–degraded type III collagen Barascuk et al., 2010 1.11 —
P4NP 7 S 7 S domain of type IV collagen Leeming et al., 2012 1.33*** 0.07
C4M MMP-2/9–degraded type IV collagen Veidal et al., 2011a 1.18** 0.03
PRO-C5 N-terminal propeptide of type V collagen — 1.31** 0.05
C6M MMP-2/9–degraded type VI collagen Veidal et al., 2011b 1.39*** 0.15
CRPM MMP–mediated CRP degradation Skjot-Arkil et al., 2012 0.88 —
BGN MMP-9–mediated biglycan degradation Genovese et al., 2013 1.82**** −0.02
ELM7 MMP7–degraded elastin Skjot-Arkil et al., 2010 0.97 —
N-MID Cathepin-degraded osteocalcin Skjot-Arkil et al., 2010 1.28 —
VCANM MMP–mediated versican degradation Barascuk et al., 2013 0.95 —
PIIINP/C3M Type III collagen turnover — 1.63**** 0.28*
PRO-C3/C3M Type III collagen turnover — 1.37*** 0.27*
P4NP/C4M Type IV collagen turnover — 1.14** 0.01
CTX-I/N-MID Bone turnover — 2.17**** 0.26*
Abbreviations: FC, fold change of serum marker levels between SSc patients and HCs; HC, healthy control; HAQ-DI, Health Assessment Questionnaire-
Disability Index; ρ, Spearman’s correlation coefﬁcient between HAQ-DI and differentially expressed serum markers; SSc, systemic sclerosis.
****BH Po0.001, ***BH Po0.01, **BH Po0.05, and *unadjusted Po0.05.
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collagen synthesis and degradation markers (PIIINP/C3M or
PRO-C3/C3M) is associated with disease activity measured by
HAQ-DI. Although anifrolumab was not associated with
PIIINP change, our results demonstrated consistent suppres-
sion of the C3M level associated with administration of the
anti-IFNAR antibody, which may result from the reduced
levels of MMP inhibitors after treatment. The decreased
PIIINP/C3M and PRO-C3/C3M ratios suggest the potential
improvement of tissue ﬁbrosis after anifrolumab administra-
tion. Furthermore, skin microarray results demonstrated
signiﬁcant suppression of ECM–related transcripts by anifro-
lumab. Numerous ﬁbrosis-related transcripts were down-
regulated by anifrolumab. Given that type I IFNs are potent
inhibitors of collagen production in vitro (Duncan and
Berman, 1987), the suppressive effects of IFN blockade on
collagen gene expression might be due to the reduction in
inﬂammation rather than a direct effect to ﬁbroblasts.
A complex interplay among activated endothelial
cell, T cell, and ﬁbroblast is involved in SSc pathogenesis.
Endothelium damage and immune cell inﬁltration may be
alleviated by anifrolumab, evidenced by the decreased
concentration of adhesion molecules and chemokines after
blockade of IFN signaling. These changes might in turn
desensitize SSc ﬁbroblast to autocrine TGF-β signaling
through the decreased expression of thrombospondins,
integrins, and TGF-β receptors, all of which are involved in
latent TGF-β activation and downstream signaling for the
stimulation of collagen synthesis (Leask, 2006). Reduced
TGF-β signaling and CTGF suppression by anifrolumab may
be responsible for the decreased expression of various ECM
components and tissue inhibitors of metalloproteinase
causing the accelerated degradation of type III collagen.
Importantly, our study was not designed to evaluate the
effect of anifrolumab on clinical measures of disease activity.
Our samples were from a Phase I trial with small sample
size and short treatment duration. As no placebo arm was
included in this open-label trial, we procured samples from
another SSc trial as controls to assess whether or not the
observed effects are speciﬁc to anifrolumab. Larger clinical
trials with randomized placebo-controlled design are required
to determine the relationship between changes in peripheral
markers and clinical responses of SSc subjects to anifrolumab
treatment.
Our anti-CD19 antibody, MEDI-551, induced a robust
reduction in the B cell and plasma cell gene signatures in both
whole-blood and skin biopsies of SSc subjects (Streicher et al.,
2014). The increase in the BAFF level after MEDI-551
administration may result from the decrease in its receptors,
or a delayed regulation of BAFF mRNA transcription following
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IFI44L
IFI27
IFIT3
MX1
TIMP1
TIMP2
TIMP3
COL1A1
COL1A2
COL3A1
COL5A1
COL5A2
ITGB1
ITGB8
TGFBR1
TGFBR2
TGFBR3
CTGF
COMP
FGFR3
THBS1
FN1
SPARC
5.0 mg kg–11.0 mg kg–10.3 mg kg–1
log2FC
Color key
–5 0
Figure 3. Skin transcripts suppressed by multiple doses of anifrolumab.
Signiﬁcant suppression of type I IFN-inducible transcripts, tissue inhibitors of
metalloproteinases (TIMPs), multiple collagens, integrins, transforming growth
factor-β (TGF-β) receptors, and other TGF-β-associated transcripts was
observed after anifrolumab administration (false discovery rate (FDR) o0.01).
The heatmap shows log 2-fold change (FC) of each transcript at day 28 relative
to pretreatment for 10 systemic sclerosis (SSc) patient who received
four weekly intravenous doses (0.3, 1.0, or 5.0 mg kg−1 per week) of
anifrolumab.
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B cell depletion (Lavie et al., 2007). Furthermore, plasma cell
and B cell gene signature reduction was positively correlated
with inhibition of collagen gene expression in skin biopsies
post treatment of MEDI-551 (Streicher et al., 2014). Thus, the
two antibodies may have an impact on SSc disease activity
through different pathways.
In summary, our study demonstrates suppressive effects of
anifrolumab on T cell activation and collagen accumulation
through which tissue ﬁbrosis of SSc subjects may be reduced.
Continued clinical studies of anifrolumab in IFN-related
diseases including trials in systemic lupus erythematosus
will further investigate the relationship between peri-
pheral markers and clinical responses to treatment with
anifrolumab.
MATERIALS AND METHODS
Clinical samples
In a Phase I, open-label clinical trial, 34 adult SSc subjects received
single (0.1, 0.3, 1.0, 3.0, 10.0, or 20.0 mg kg− 1) or a 4-week repeated
intravenous doses (0.3, 1.0, or 5.0 mg kg−1 per week) of anifrolumab
(Study MI-CP180). The detailed study design and safety proﬁles have
been reported previously (Goldberg et al., 2014). MEDI-551 is an
investigational human IgG1κ mAb that binds to CD19 and depletes B
cells. A Phase I, randomized, double-blind, placebo-controlled
clinical trial has been conducted to evaluate the safety and
tolerability of escalating single doses of MEDI-551 in adult SSc
subjects (Study MI-CP200). Identical inclusion/exclusion criteria
were used in the two trials. Stable concomitant medication was
allowed unless the treatment met the exclusion criterion. Both study
protocols were reviewed and approved by Institutional Review
Boards or independent ethics committee of each participating center
before study initiation. Written informed consent was obtained from
each participant before study entry.
Serum proteomics proﬁling
Sera from 30 HCs, 26 SSc patients at baseline and day 56 after
anifrolumab administration, along with 21 SSc patients at baseline
and day 85 after either placebo or MEDI-551 administration were
procured for the measurement of 93 proteins including chemokines,
cytokines, growth factors, soluble receptors, and adhesion molecules
(Supplementary Table S2 online). Serum samples were kept frozen
at − 80 °C before shipment to Myriad RBM (Austin, TX) for a
multiplexed immunoassay based on the Luminex xMAP technology.
Samples were processed and analyzed at Myriad RBM according to
standard operating procedure.
Serum markers for ECM turnover
The amino-terminal propeptides of type I procollagen and PIIINP
were measured by electrochemiluminescent immunoassay and
radioimmunoassay techniques respectively. Furthermore, we ana-
lyzed 14 ﬁngerprint markers for ECM turnover by ELISA in SSc
subjects. Brieﬂy, serum samples from 30 HCs and up to 59 SSc
patients before and after treatments were analyzed by Paciﬁc
Biomarkers (Seattle, WA) for amino-terminal propeptides of type I
procollagen/PIIINP analysis and Nordic Biosciences (Herlev, Den-
mark) for the measurement of the additional ECM markers. Detailed
experimental procedures for each marker may be found in references
listed in Table 3.
Whole-genome microarray study
PAXGene whole-blood tubes were collected from 29 SSc patients at
baseline and day 56 after anifrolumab administration, and skin
biopsies were procured from 10 SSc patients at baseline and day 28
after multiple doses of anifrolumab administration. Total RNA was
extracted using the PAXgene Blood RNA Kit and the Qiagen RNeasy
Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany), respectively.
Biotin-labeled cRNA was generated from total RNA and fragmented
for hybridization on Affymetrix Human Genome U133 Plus
GeneChip arrays (Affymetrix, Santa Clara, CA). Type I IFN gene
signature was calculated by whole-blood expression levels of ﬁve
type I IFN–inducible genes (RSAD2, IFI44, IFI44L, IFI27, and IFI6)
and used as a PD marker for anifrolumab (Goldberg et al., 2014). The
microarray data has been deposited in Gene Expression Omnibus
(GEO) under accession number GSE65336.
Statistical analysis
Student’s t-test or analysis of variance was used to compare
continuous variables among different groups, whereas Fisher’s exact
test was used for discrete variables. Multiple comparison problems
were controlled by BH adjustment (Benjamini et al., 2001).
Differentially expressed genes were identiﬁed by signiﬁcance
analysis of microarray (Tusher et al., 2001). All correlations were
assessed by Spearman’s correlation tests and the signiﬁcance was
determined via the asymptotic t approximation followed by BH
adjustment.
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